These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

200 related items for PubMed ID: 32905289

  • 1. Association between urinary biomarkers and disease progression in adults with autosomal dominant polycystic kidney disease.
    Segarra-Medrano A, Martin M, Agraz I, Vilaprinyó M, Chamoun B, Jatem E, Molina M, Colàs-Campàs L, Garcia-Carrasco A, Roche S.
    Clin Kidney J; 2020 Aug; 13(4):607-612. PubMed ID: 32905289
    [Abstract] [Full Text] [Related]

  • 2. Rapid Progression of Autosomal Dominant Polycystic Kidney Disease: Urinary Biomarkers as Predictors.
    Messchendorp AL, Meijer E, Visser FW, Engels GE, Kappert P, Losekoot M, Peters DJM, Gansevoort RT, on behalf of the DIPAK-1 study investigators.
    Am J Nephrol; 2019 Aug; 50(5):375-385. PubMed ID: 31600749
    [Abstract] [Full Text] [Related]

  • 3. Urinary Biomarkers to Identify Autosomal Dominant Polycystic Kidney Disease Patients With a High Likelihood of Disease Progression.
    Messchendorp AL, Meijer E, Boertien WE, Engels GE, Casteleijn NF, Spithoven EM, Losekoot M, Burgerhof JGM, Peters DJM, Gansevoort RT, DIPAK Consortium.
    Kidney Int Rep; 2018 Mar; 3(2):291-301. PubMed ID: 29725632
    [Abstract] [Full Text] [Related]

  • 4. Changes in tubular biomarkers with dietary intervention and metformin in patients with autosomal dominant polycystic kidney disease: a post-hoc analysis of two clinical trials.
    Wang W, You Z, Steele CN, Gitomer B, Chonchol M, Nowak KL.
    BMC Nephrol; 2024 Jun 25; 25(1):206. PubMed ID: 38918734
    [Abstract] [Full Text] [Related]

  • 5. Cystatin C estimated glomerular filtration rate to assess renal function in early stages of autosomal dominant polycystic kidney disease.
    Sans L, Radosevic A, Quintian C, Montañés R, Gràcia S, Vilaplana C, Mojal S, Ballarin JA, Fernández-Llama P, Torra R, Pascual J.
    PLoS One; 2017 Jun 25; 12(3):e0174583. PubMed ID: 28346513
    [Abstract] [Full Text] [Related]

  • 6. Urinary biomarkers at early ADPKD disease stage.
    Petzold K, Poster D, Krauer F, Spanaus K, Andreisek G, Nguyen-Kim TD, Pavik I, Ho TA, Serra AL, Rotar L.
    PLoS One; 2015 Jun 25; 10(4):e0123555. PubMed ID: 25875363
    [Abstract] [Full Text] [Related]

  • 7. Baseline total kidney volume and the rate of kidney growth are associated with chronic kidney disease progression in Autosomal Dominant Polycystic Kidney Disease.
    Yu ASL, Shen C, Landsittel DP, Harris PC, Torres VE, Mrug M, Bae KT, Grantham JJ, Rahbari-Oskoui FF, Flessner MF, Bennett WM, Chapman AB, Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP).
    Kidney Int; 2018 Mar 25; 93(3):691-699. PubMed ID: 29290310
    [Abstract] [Full Text] [Related]

  • 8. Age- and height-adjusted total kidney volume growth rate in autosomal dominant polycystic kidney diseases.
    Higashihara E, Yamamoto K, Kaname S, Okegawa T, Tanbo M, Yamaguchi T, Shigemori K, Miyazaki I, Yokoyama K, Nutahara K.
    Clin Exp Nephrol; 2019 Jan 25; 23(1):100-111. PubMed ID: 30097754
    [Abstract] [Full Text] [Related]

  • 9. Increased urinary Angiotensinogen/Creatinine (AGT/Cr) ratio may be associated with reduced renal function in autosomal dominant polycystic kidney disease patients.
    Park HC, Kang AY, Jang JY, Kim H, Han M, Oh KH, Kim SH, Noh JW, Cheong HI, Hwang YH, Ahn C.
    BMC Nephrol; 2015 Jun 20; 16():86. PubMed ID: 26092580
    [Abstract] [Full Text] [Related]

  • 10. The correlation between kidney volume and measured glomerular filtration rate in an Asian ADPKD population: a prospective cohort study.
    Phakdeekitcharoen B, Treesinchai W, Wibulpolprasert P, Boongird S, Klytrayong P.
    BMC Nephrol; 2021 May 15; 22(1):178. PubMed ID: 33992075
    [Abstract] [Full Text] [Related]

  • 11. Association of urinary biomarkers with disease severity in patients with autosomal dominant polycystic kidney disease: a cross-sectional analysis.
    Meijer E, Boertien WE, Nauta FL, Bakker SJ, van Oeveren W, Rook M, van der Jagt EJ, van Goor H, Peters DJ, Navis G, de Jong PE, Gansevoort RT.
    Am J Kidney Dis; 2010 Nov 15; 56(5):883-95. PubMed ID: 20888104
    [Abstract] [Full Text] [Related]

  • 12. Association of arginine vasopressin surrogate marker urinary copeptin with severity of autosomal dominant polycystic kidney disease (ADPKD).
    Nakajima A, Lu Y, Kawano H, Horie S, Muto S.
    Clin Exp Nephrol; 2015 Dec 15; 19(6):1199-205. PubMed ID: 25715868
    [Abstract] [Full Text] [Related]

  • 13. KIM-1 and Kidney Disease Progression in Autosomal Dominant Polycystic Kidney Disease: HALT-PKD Results.
    Griffin BR, You Z, Noureddine L, Gitomer B, Perrenoud L, Wang W, Chonchol M, Jalal D, the HALT Investigators.
    Am J Nephrol; 2020 Dec 15; 51(6):473-479. PubMed ID: 32541154
    [Abstract] [Full Text] [Related]

  • 14. Association of Baseline Urinary Metabolic Biomarkers with ADPKD Severity in TAME-PKD Clinical Trial Participants.
    Hallows KR, Althouse AD, Li H, Saitta B, Abebe KZ, Bae KT, Miskulin DC, Perrone RD, Seliger SL, Watnick TJ.
    Kidney360; 2021 May 15; 2(5):795-808. PubMed ID: 34316721
    [Abstract] [Full Text] [Related]

  • 15. Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease.
    Chapman AB, Bost JE, Torres VE, Guay-Woodford L, Bae KT, Landsittel D, Li J, King BF, Martin D, Wetzel LH, Lockhart ME, Harris PC, Moxey-Mims M, Flessner M, Bennett WM, Grantham JJ.
    Clin J Am Soc Nephrol; 2012 Mar 15; 7(3):479-86. PubMed ID: 22344503
    [Abstract] [Full Text] [Related]

  • 16. Image texture features predict renal function decline in patients with autosomal dominant polycystic kidney disease.
    Kline TL, Korfiatis P, Edwards ME, Bae KT, Yu A, Chapman AB, Mrug M, Grantham JJ, Landsittel D, Bennett WM, King BF, Harris PC, Torres VE, Erickson BJ, CRISP Investigators.
    Kidney Int; 2017 Nov 15; 92(5):1206-1216. PubMed ID: 28532709
    [Abstract] [Full Text] [Related]

  • 17. Patient-Reported Outcomes Measures, Polycystic Kidney Disease Burden, and Outcomes in Autosomal Dominant Polycystic Kidney Disease.
    Oberdhan D, Yarlas A, Bjorner JB, Krasa H.
    Kidney Med; 2024 Jan 15; 6(1):100755. PubMed ID: 38192435
    [Abstract] [Full Text] [Related]

  • 18. Urinary Angiotensinogen in addition to Imaging Classification in the Prediction of Renal Outcome in Autosomal Dominant Polycystic Kidney Disease.
    Park HC, Kim J, Cho A, Kim DH, Lee YK, Ryu H, Kim H, Oh KH, Oh YK, Hwang YH, Lee KB, Kim SW, Kim YH, Lee J, Ahn C, KNOW-CKD Investigators Group.
    J Korean Med Sci; 2020 Jun 08; 35(22):e165. PubMed ID: 32508065
    [Abstract] [Full Text] [Related]

  • 19. Coregulation Analysis of Mechanistic Biomarkers in Autosomal Dominant Polycystic Kidney Disease.
    Leierer J, Perco P, Hofer B, Eder S, Dzien A, Kerschbaum J, Rudnicki M, Mayer G.
    Int J Mol Sci; 2021 Jun 26; 22(13):. PubMed ID: 34206927
    [Abstract] [Full Text] [Related]

  • 20. Health-related quality of life in patients with autosomal dominant polycystic kidney disease and CKD stages 1-4: a cross-sectional study.
    Miskulin DC, Abebe KZ, Chapman AB, Perrone RD, Steinman TI, Torres VE, Bae KT, Braun W, Winklhofer FT, Hogan MC, Rahbari-Oskoui F, Moore CG, Flessner MF, Schrier RW, HALT-PKD Study.
    Am J Kidney Dis; 2014 Feb 26; 63(2):214-26. PubMed ID: 24183837
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.